Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

This treatment has been approved for sale to the public.
Sponsor:
Collaborator:
Multiple Myeloma Research Foundation
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01410500
First received: August 2, 2011
Last updated: May 1, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This treatment has been approved for sale to the public.
  Study Completion Date: No date given
  Primary Completion Date: No date given